877 related articles for article (PubMed ID: 22323472)
1. Cardiovascular biology of the incretin system.
Ussher JR; Drucker DJ
Endocr Rev; 2012 Apr; 33(2):187-215. PubMed ID: 22323472
[TBL] [Abstract][Full Text] [Related]
2. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors.
Neumiller JJ
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S16-29. PubMed ID: 19801361
[TBL] [Abstract][Full Text] [Related]
3. The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.
Morales J
Postgrad Med; 2011 Nov; 123(6):189-201. PubMed ID: 22104467
[TBL] [Abstract][Full Text] [Related]
4. Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.
Nauck M
Diabetes Obes Metab; 2016 Mar; 18(3):203-16. PubMed ID: 26489970
[TBL] [Abstract][Full Text] [Related]
5. Cardiovascular Actions and Clinical Outcomes With Glucagon-Like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors.
Nauck MA; Meier JJ; Cavender MA; Abd El Aziz M; Drucker DJ
Circulation; 2017 Aug; 136(9):849-870. PubMed ID: 28847797
[TBL] [Abstract][Full Text] [Related]
6. Emerging cardiovascular actions of the incretin hormone glucagon-like peptide-1: potential therapeutic benefits beyond glycaemic control?
Grieve DJ; Cassidy RS; Green BD
Br J Pharmacol; 2009 Aug; 157(8):1340-51. PubMed ID: 19681866
[TBL] [Abstract][Full Text] [Related]
7. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
Freeman JS
Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
[TBL] [Abstract][Full Text] [Related]
8. The incretin system and its role in type 2 diabetes mellitus.
Holst JJ; Vilsbøll T; Deacon CF
Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
[TBL] [Abstract][Full Text] [Related]
9. Glucagon-like peptide-1 and its cardiovascular effects.
Heo KS; Fujiwara K; Abe J
Curr Atheroscler Rep; 2012 Oct; 14(5):422-8. PubMed ID: 22878937
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of incretin based therapies: clinical trial data.
White J
J Am Pharm Assoc (2003); 2009; 49 Suppl 1():S30-40. PubMed ID: 19801363
[TBL] [Abstract][Full Text] [Related]
11. Differentiating among incretin therapies: a multiple-target approach to type 2 diabetes.
Cornell S
J Clin Pharm Ther; 2012 Oct; 37(5):510-24. PubMed ID: 22436069
[TBL] [Abstract][Full Text] [Related]
12. Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease.
Panchapakesan U; Mather A; Pollock C
Clin Sci (Lond); 2013 Jan; 124(1):17-26. PubMed ID: 22963445
[TBL] [Abstract][Full Text] [Related]
13. Incretin-based therapies and cardiovascular risk.
Mannucci E; Dicembrini I
Curr Med Res Opin; 2012 May; 28(5):715-21. PubMed ID: 22439700
[TBL] [Abstract][Full Text] [Related]
14. Beyond glucose lowering: glucagon-like peptide-1 receptor agonists, body weight and the cardiovascular system.
Vergès B; Bonnard C; Renard E
Diabetes Metab; 2011 Dec; 37(6):477-88. PubMed ID: 21871831
[TBL] [Abstract][Full Text] [Related]
15. The entero-insular axis: implications for human metabolism.
Ranganath LR
Clin Chem Lab Med; 2008; 46(1):43-56. PubMed ID: 18020966
[TBL] [Abstract][Full Text] [Related]
16. CARDIOVASCULAR OUTCOME TRIALS OF THE INCRETIN-BASED THERAPIES: WHAT DO WE KNOW SO FAR?
Mora PF; Johnson EL
Endocr Pract; 2017 Jan; 23(1):89-99. PubMed ID: 27819769
[TBL] [Abstract][Full Text] [Related]
17. Incretin pharmacology: a review of the incretin effect and current incretin-based therapies.
Neumiller JJ
Cardiovasc Hematol Agents Med Chem; 2012 Dec; 10(4):276-88. PubMed ID: 22827291
[TBL] [Abstract][Full Text] [Related]
18. Update on incretin hormones.
Phillips LK; Prins JB
Ann N Y Acad Sci; 2011 Dec; 1243():E55-74. PubMed ID: 22545749
[TBL] [Abstract][Full Text] [Related]
19. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
Jellinger PS
Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
[TBL] [Abstract][Full Text] [Related]
20. Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy.
Avogaro A; Vigili de Kreutzenberg S; Fadini GP
Curr Diab Rep; 2014; 14(5):483. PubMed ID: 24676508
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]